Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635256 | 0.95 | CYP3A4 (0.44) | CYP3A4USP2IDO1CNR1L3MBTL1 | |
| SCHEMBL2635011 | 0.93 | CYP3A4 (0.39) | CYP3A4USP2IDO1CNR1L3MBTL1 | |
| SCHEMBL2635553 | 0.92 | CNR1 (0.42) | CYP3A4USP2IDO1CNR1L3MBTL1 | |
| SCHEMBL2635300 | 0.92 | IDO1 (0.40) | CYP3A4USP2IDO1CNR1L3MBTL1 | |
| SCHEMBL2634767 | 0.89 | HTT (0.47) | CYP3A4USP2CNR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL2635087 | 0.89 | CYP3A4 (0.39) | CYP3A4USP2IDO1CNR1L3MBTL1 | |
| SCHEMBL2635794 | 0.88 | ALDH1A1 (0.49) | CYP3A4USP2L3MBTL1ALDH1A1NAMPT | |
| SCHEMBL2637373 | 0.85 | IDO1 (0.49) | CYP3A4USP2IDO1CNR1L3MBTL1 | |
| SCHEMBL2635267 | 0.84 | HTT (0.47) | CYP3A4USP2CNR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL2635754 | 0.84 | ALDH1A1 (0.49) | CYP3A4USP2L3MBTL1ALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | claimed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | claimed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | claimed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | CYP3A4 3523/4885USP2 3817/4885IDO1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.